Bosaya (denosumab-kyqq) NDC 83257-029

NDC codes

FDA NDC Directory

Product NDC (as listed)83257-029Labeler and product segments. Claims need a package NDC.

Product NDC at billing width83257-0029Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
83257-029-41	83257002941	1 SYRINGE in 1 CARTON (83257-029-41) / 1 mL in 1 SYRINGEMarketed from Jan 5, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Bosaya
Generic name (nonproprietary): denosumab-kyqq
Active ingredients: Denosumab — 60 mg/mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Biocon Biologics Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761436
Marketing start: Jan 5, 2026
Listing expires: Dec 31, 2027
Other FDA classes: RANK Ligand Blocking Activity (Mechanism)
Identifiers: Product ID 83257-029_292f2c96-0e7f-7cf6-0106-4adfedc03423SPL ID 292f2c96-0e7f-7cf6-0106-4adfedc03423SPL set ID 1e5e8c88-3c65-3076-e44b-02d92c2d343dRxCUI 2725928, 2725935UNII 4EQZ6YO2HI
Pharmacologic class: RANK Ligand Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0897 — Injection, denosumab, 1 mg

Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.

Denosumab biosimilars have their own HCPCS codes.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N483257002941 followed by a unit qualifier and the quantity

Package 83257-0029-41. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 27, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Bosaya is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Bosaya is indicated for the treatment …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761436

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761436
Product	Strength	Form · route	Labeler	Product NDC
Aukelsodenosumab-kyqq	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	Biocon Biologics Inc.	83257-030